| scholarly article | Q13442814 |
| P2093 | author name string | B Kurdi-Haidar | |
| S B Howell | |||
| H Zheng | |||
| R Gordon | |||
| R Fishel | |||
| D Fink | |||
| S Aebi | |||
| C R Boland | |||
| M Koi | |||
| R D Christen | |||
| B Cenni | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA mismatch repair | Q2984243 |
| P304 | page(s) | 3087-3090 | |
| P577 | publication date | 1996-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Loss of DNA mismatch repair in acquired resistance to cisplatin | |
| P478 | volume | 56 |
| Q39869621 | 5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. |
| Q36906569 | A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity |
| Q36643443 | A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer |
| Q28283356 | A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer |
| Q37639735 | A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients |
| Q37799102 | Aberrant expression of alternative DNA polymerases: A source of mutator phenotype as well as replicative stress in cancer |
| Q83174919 | Accelerated growth of intestinal tumours after radiation exposure in Mlh1-knockout mice: evaluation of the late effect of radiation on a mouse model of HNPCC |
| Q33832043 | Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma |
| Q33919232 | Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer |
| Q28547861 | Antitumor Activity of a 5-Hydroxy-1H-Pyrrol-2-(5H)-One-Based Synthetic Small Molecule In Vitro and In Vivo |
| Q39654767 | Antitumor activity of satraplatin in cisplatin‐resistant oral squamous cell carcinoma cells |
| Q34517743 | Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. |
| Q37031517 | Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. |
| Q35895420 | Carcinogen-specific induction of genetic instability. |
| Q35838174 | Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function |
| Q34089685 | Cellular Responses to Cisplatin‐Induced DNA Damage |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q36693771 | Chemotherapeutic implications in microsatellite unstable colorectal cancer |
| Q53914199 | Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation? |
| Q40653510 | Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells |
| Q33948747 | Clinical perspectives on platinum resistance |
| Q92980013 | Clinical value of MLH1-negative circulating tumor cells in lung cancer patients |
| Q33798999 | Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions |
| Q37729428 | Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies |
| Q58699219 | DNA repair pathways and cisplatin resistance: an intimate relationship |
| Q34042848 | DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular Consequences |
| Q38868401 | Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer |
| Q34795259 | DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation |
| Q39581441 | Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays |
| Q34625375 | Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts |
| Q37323498 | Drug resistance and DNA repair in leukaemia |
| Q41726020 | Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival |
| Q37122036 | Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity |
| Q55044222 | Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. |
| Q39901887 | Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells |
| Q36641429 | Extensive molecular screening for hereditary non-polyposis colorectal cancer |
| Q34265940 | Features of ovarian cancer in Lynch syndrome (Review). |
| Q27671829 | Flanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-Links |
| Q37190264 | Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. |
| Q38755812 | Functional and physical interaction between the mismatch repair and FA-BRCA pathways |
| Q37113732 | Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. |
| Q34049228 | Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. |
| Q36022274 | Genetic and epigenetic changes in human prostate cancer |
| Q37933098 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers |
| Q91633487 | HDAC6 regulates DNA damage response via deacetylating MLH1 |
| Q35547560 | Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease |
| Q38725347 | HuCOP1 contributes to the regulation of DNA repair in keratinocytes. |
| Q54064735 | Immunohistochemical analysis of DNA 'mismatch-repair' enzyme human Mut-S-Homologon-2 in ovarian carcinomas. |
| Q24648193 | Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2 |
| Q36617515 | Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells |
| Q34781192 | Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. |
| Q28388726 | Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research |
| Q24553992 | Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin |
| Q24527652 | Ku86 autoantigen related protein-1 transcription initiates from a CpG island and is induced by p53 through a nearby p53 response element |
| Q37599111 | Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest |
| Q36316604 | Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. |
| Q37577939 | Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial |
| Q36617626 | Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin |
| Q30495565 | Low frequency of replication errors in primary nervous system tumours |
| Q37287437 | MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. |
| Q24535964 | MSH2 is essential for the preservation of genome integrity and prevents homeologous recombination in the moss Physcomitrella patens |
| Q24810372 | MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability |
| Q24556572 | Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2 |
| Q35165126 | MicroRNA-mediated drug resistance in breast cancer |
| Q60629555 | Microsatellite instability in colorectal cancer |
| Q24627393 | Microsatellite instability in colorectal cancer |
| Q83835402 | Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications |
| Q33252378 | Mismatch repair and treatment resistance in ovarian cancer |
| Q36540568 | Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer |
| Q36617973 | Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents |
| Q37696965 | Mismatch repair deficient colorectal cancer in the era of personalized treatment |
| Q33758325 | Mismatch repair proteins are activators of toxic responses to chromium-DNA damage |
| Q34678905 | Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. |
| Q42789116 | Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics |
| Q37666255 | Molecular mechanisms behind the resistance of cisplatin in germ cell tumours |
| Q35758048 | Molecular mechanisms of resistance and toxicity associated with platinating agents |
| Q36057058 | Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer |
| Q35171602 | Multiple biochemical activities of NM23/NDP kinase in gene regulation |
| Q24306821 | MutS homologue hMSH5: role in cisplatin-induced DNA damage response |
| Q24531843 | No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin |
| Q36254803 | Nucleotide excision repair and anti-cancer chemotherapy |
| Q24644933 | Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs |
| Q34159515 | Parameters of Reserpine Analogs That Induce MSH2/MSH6‐Dependent Cytotoxic Response |
| Q30832102 | Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells |
| Q36350781 | Predicting the impact of Lynch syndrome-causing missense mutations from structural calculations |
| Q35875960 | Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? |
| Q36512211 | Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2. |
| Q26778143 | Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts |
| Q37444790 | Protein and genome evolution in Mammalian cells for biotechnology applications |
| Q39464747 | Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers |
| Q36565271 | Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems |
| Q41886077 | Recognition of DNA alterations by the mismatch repair system |
| Q51137792 | Renoprotective effects of antioxidants against cisplatin nephrotoxicity. |
| Q24610838 | Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications |
| Q37249597 | Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance |
| Q37295775 | Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients |
| Q34625095 | Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. |
| Q33954219 | Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1 |
| Q27644753 | Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link † , ‡ |
| Q37128242 | Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology |
| Q26863585 | Systems biology of cisplatin resistance: past, present and future |
| Q34786141 | The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations |
| Q33762979 | The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside |
| Q43233321 | The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. |
| Q37038987 | The history of Lynch syndrome |
| Q33721800 | The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint |
| Q28274343 | The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer |
| Q33592366 | The role of mismatch repair in the prevention of base pair mutations in Saccharomyces cerevisiae |
| Q37269683 | Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer |
| Q35676066 | YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. |
| Q36620488 | hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. |
| Q34695775 | hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis |
| Q36538872 | hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage |
| Q35692651 | miR-34 and p53: New Insights into a Complex Functional Relationship |
Search more.